The effect of pneumococcal polysaccharide vaccine in a mouse model of allergic rhinitis

Otolaryngology - Head and Neck Surgery (United States)

Volumn 148, Issue 3, 2013, Pages 383-390

  Shin, Ji Hyeon ^a   Kim, Boo Young ^a   Park, Hyang Rim ^a   Kim, Sung Won ^a   Kim, Soo Whan ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

A mouse model; Allergic rhinitis; Pneumococcal vaccine; Polysaccharide vaccine; Regulatory T cells; Sensitization; Th2 cells

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 13; MESSENGER RNA; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR T BET; ALLERGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; INTERFERON; TRANSCRIPTION FACTOR GATA 3;

ALLERGIC RHINITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CD4+ CD25+ T LYMPHOCYTE; CONFERENCE PAPER; CONTROLLED STUDY; DERMATOPHAGOIDES FARINAE; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; EOSINOPHIL COUNT; FEMALE; FLOW CYTOMETRY; IMMUNOGLOBULIN BLOOD LEVEL; IN VIVO STUDY; LAMINA PROPRIA; MONONUCLEAR CELL; MOUSE; NONHUMAN; NOSE MUCOSA; NOSE MUCUS; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; SENSITIZATION; SPLEEN; TH2 CELL; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; CYTOLOGY; DISEASE MODEL; GENETICS; IMMUNOLOGY; PERENNIAL RHINITIS;

ALLERGENS; ANIMALS; DERMATOPHAGOIDES FARINAE; DISEASE MODELS, ANIMAL; EOSINOPHILS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GATA3 TRANSCRIPTION FACTOR; IMMUNOGLOBULIN E; INTERFERONS; INTERLEUKIN-10; INTERLEUKIN-13; MICE; MICE, INBRED BALB C; NASAL LAVAGE FLUID; NASAL MUCOSA; PNEUMOCOCCAL VACCINES; REAL-TIME POLYMERASE CHAIN REACTION; RHINITIS, ALLERGIC, PERENNIAL; RNA, MESSENGER; SPLEEN;

MLCS; MLOWN;

EID: 84876096984     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599812472864     Document Type: Conference Paper

References (22)

1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(suppl 86):8-160. (Pubitemid 351357811)
2. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299:1259-1260. (Pubitemid 19280051)
3. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med. 1995;333:1618-1624.
4. Pesek R, Lockey R. Vaccination of adults with asthma and COPD. Allergy. 2011;66:25-31.
5. Obert J, Burgel PR. Pneumococcal infections: association with asthma and COPD. Med Mal Infect. 2012;42:188-192.
6. Bisgaard H, Hermansen MN, Buchvald F, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med. 2007;357:1487-1495. (Pubitemid 47572634)
7. Talbot TR, Hartert TV, Mitchel E, et al. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med. 2005;352:2082-2090. (Pubitemid 40667531)
8. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of proteinpolysaccharide conjugate vaccine. N Engl J Med. 2003;348: 1737-1746. (Pubitemid 36514704)
9. Lu PJ, Nuorti JP. Nuorti. Uptake of pneumococcal polysaccharide vaccination among working-age adults with underlying medical conditions, United States, 2009. Am J Epidemiol. 2012;175:827-837.
10. Preston JA, Essilfie AT, Horvat JC, et al. Inhibition of allergic airways disease by immunomodulatory therapy with whole killed Streptococcus pneumoniae. Vaccine. 2007;25:8154-8162. (Pubitemid 350054909)
11. Thorburn AN, O'Sullivan BJ, Thomas R, et al. Pneumococcal conjugate vaccine-induced regulatory T cells suppress the development of allergic airways disease. Thorax. 2010;65: 1053-1060.
12. Xu G, Cheng L, Wen W, et al. Inverse association between T-cell immunoglobulin and mucin domain-1 and T-bet in a mouse model of allergic rhinitis. Laryngoscope. 2007;117: 960-964. (Pubitemid 46869827)
13. San Román B, Irache JM, Gómez S, Gamazo C, Espuelas S. Co-delivery of ovalbumin and CpG motifs into microparticles protected sensitized mice from anaphylaxis. Int Arch Allergy Immunol. 2009;149:111-118.
14. Klemets P, Lyytikäinen O, Ruutu P, et al. Risk of invasive pneumococcal infections among working age adults with asthma. Thorax. 2010;65:698-702.
15. Jung JA, Kita H, Yawn BP, et al. Increased risk of serious pneumococcal disease in patients with atopic conditions other than asthma. J Allergy Clin Immunol. 2010;125:217-221.
16. Thorburn AN, Hansbro PM, Gibson PG. Pneumococcal vaccines for allergic airways diseases. Expert Opin Biol Ther. 2009;9:621-629.
17. Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010; 59:1-18.
18. Musher DM, Manof SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis. 2010;201: 516-524.
19. Ansaldi F, Turello V, Lai P, et al. Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and non-invasive pneumococcal infection in elderly people: a large-scale retrospective cohort study. J Int Med Res. 2005; 33:490-500. (Pubitemid 41388386)
20. Sheikh A, Alves B, Dhami S. Pneumococcal vaccine for asthma. Cochrane Database Syst Rev. 2002;(1):CD002165.
21. Preston JA, Thorburn AN, Starkey MR, et al. Streptococcus pneumoniae infection suppresses allergic airways disease by inducing regulatory T-cells. Eur Respir J. 2011;37:53-64.
22. Thorburn AN, Foster PS, Gibson PG, et al. Components of Streptococcus pneumoniae suppress allergic airways disease and NKT cells by inducing regulatory T cells. J Immunol. 2012;188:4611-4620.